Securities code: Sirio Pharma Co.Ltd(300791) securities abbreviation: Sirio Pharma Co.Ltd(300791) announcement Code: 2022030 securities code: 123113 securities abbreviation: xianle convertible bonds
Announcement on correction of 2021 Annual Report
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Sirio Pharma Co.Ltd(300791) (hereinafter referred to as “the company”) disclosed the full text of the 2021 annual report on the gem information disclosure website designated by the CSRC on April 12, 2022 (Announcement No.: 2022015). After the post audit, it is found that due to the negligence of the staff, some data amounts are incorrectly filled in because of the “10000 yuan” unit, which is hereby corrected. Relevant contents before and after correction are as follows:
1、 “7. Analysis of investment situation” in “section III Management Discussion and analysis” and “5. Use of raised funds”
Before correction: (1) overall use of raised funds √ applicable □ not applicable
Unit: 10000 yuan
Cumulative not yet reported
During the period, the total amount of funds raised by changing the use of idle and changing the purpose of raising for two years in the current period has been used, the raised funds have been used for the purpose of raising accumulatively, the raised funds have not been used, the total amount of funds raised in the way of raising funds in the previous years, the total amount of funds raised for the purpose of raising funds Example of the ratio of the total amount of fund-raising funds and the total amount of funds removed
deposit
Raised in 2021
1013408575624901140151449011401514 0.00% 53505970821 0 fund raising
Jin Zhuan
household
Total — 1013408575624901140151449011401514 0.00% 53505970821 — 0
Description of the overall use of raised funds
With the approval of the reply on the registration of Sirio Pharma Co.Ltd(300791) issuing convertible corporate bonds to unspecified objects (zjxk [2021] No. 927) issued by China Securities Regulatory Commission (hereinafter referred to as “CSRC”), the company issues convertible corporate bonds to unspecified objects
10248929 convertible corporate bonds, each with a face value of 100 yuan and a total raised capital of 1024892900 yuan. After deducting the recommendation fee and underwriting fee of 8.7254 million yuan, the balance of raised capital of 1016167500 yuan has been transferred to the designated account of the company, of which 2.7589 million yuan (excluding tax) has not been deducted from the issuance expenses such as recommendation fee, audit and verification fee and lawyer fee. The net amount of funds actually raised this time is 1013408600 yuan. Huaxing Certified Public Accountants (special general partnership) has issued Sirio Pharma Co.Ltd(300791) capital verification report (Huaxing Yan Zi [2021] No. 21 Shenzhen Zhongheng Huafa Co.Ltd(000020) 045) and verified and confirmed the receipt of the above raised funds.
After correction: (1) overall use of raised funds √ applicable □ not applicable
Unit: 10000 yuan
In the reporting period, the total amount of raised funds has changed and the purpose has not been used in the current period. The total amount of raised funds raised in the year of raising has not been used for more than years. The total amount of raised funds raised in the purpose of raising funds. The total amount of raised funds raised in the purpose of raising funds. The total amount of raised funds raised in the purpose of raising funds and the total amount of raised funds Proportion of total amount of contribution
2021 raised and deposited in raised
1013408649011404901140 0.00% 5350597 special fund account 0
Total — 1013408649011404901140 0.00% 5350597 — 0
Description of the overall use of raised funds
With the approval of the reply on the registration of Sirio Pharma Co.Ltd(300791) issuing convertible corporate bonds to unspecified objects (zjxk [2021] No. 927) issued by China Securities Regulatory Commission (hereinafter referred to as “CSRC”), the company issues convertible corporate bonds to unspecified objects
10248929 convertible corporate bonds, each with a face value of 100 yuan and a total raised capital of 1024892900 yuan. After deducting the recommendation fee and underwriting fee of 8.7254 million yuan, the balance of raised capital of 1016167500 yuan has been transferred to the designated account of the company, of which 2.7589 million yuan (excluding tax) has not been deducted from the issuance expenses such as recommendation fee, audit and verification fee and lawyer fee. The net amount of funds actually raised this time is 1013408600 yuan.
Huaxing Certified Public Accountants (special general partnership) has issued Sirio Pharma Co.Ltd(300791) capital verification report (Huaxing Yan Zi [2021] No. 21 Shenzhen Zhongheng Huafa Co.Ltd(000020) 045) and verified and confirmed the receipt of the above raised funds.
2、 “7. Analysis of investment status” in “section IV corporate governance” and “5. Use of raised funds”
Before correction:
3. Remuneration of directors, supervisors and senior managers
In 2021, the company has 7 directors, among which Mr. Lin Peiqing, Ms. Chen Qiong, Ms. Yang Rui and Mr. Yao Zhuangmin are in-service employees of the company. They receive post salary and performance evaluation reward according to the unified salary management system of the company’s employees, and do not enjoy additional director remuneration; Independent directors Mr. Zhu Guilong, Mr. Hu Shiming and Mr. Gao Jian receive an annual allowance of 120000 yuan for independent directors according to the proposal on determining the allowance scheme for independent directors of the third board of directors deliberated and adopted at the first extraordinary general meeting of the company in 2021.
In 2021, the company had three supervisors, all in-service employees of the company, who received post wages and performance assessment rewards according to the unified salary management system of the company’s employees. In addition, they received an annual supervisor allowance of 20000 yuan according to the proposal on determining the supervisor allowance of the third session of the board of supervisors deliberated and approved by the company’s first extraordinary general meeting in 2021.
In 2021, Ms. Zheng Liqun, deputy general manager, chief financial officer and Secretary of the board of directors of the company, as an employee of the company, obtained post salary and performance evaluation reward according to the unified salary management system of the company’s employees.
In 2021, as an employee of the company, Mr. Wu Zhiwei, the deputy general manager of the company, obtained post salary and performance evaluation reward according to the unified salary management system of the company’s employees. Remuneration of directors, supervisors and senior managers of the company during the reporting period
Unit: 10000 yuan
Name position gender age employment status whether the total pre tax remuneration of the company’s related parties is paid from the company
Chairman Lin Peiqing, current general manager 17957
Chen Qiong, director and deputy general manager, female 56, currently 143535000 no
Yang Rui, director and deputy general manager, female 52, currently 143535000 no
Yao Zhuangmin, director, male 52, currently 128410000 no
Zhu Guilong, independent director, male 58, current 3000000 no
Hu Shiming, independent director, male 53, current 3000000 no
Gao Jian independent director male 50 current 3000000 no
Xie yingyu, chairman of the board of supervisors, female 40, currently 28 Chenguang Biotech Group Co.Ltd(300138) no
Zhou Xiangchun, supervisor, male 49, currently 49957056 no
Zhang Meibin, supervisor, male 34, currently 30115671 no
Is Zheng Liqun, deputy general manager, chief financial officer and Dong NV currently employed
Secretary 51117903750
Wu Zhiwei, deputy general manager, male 46, currently 354334444 no
Lv Yuan independent director male 67 leaves office 4232877 no
Yang runindependent director female 46 leaves office 4232877 no
Wu Jing independent director female 40 leaves 4232877 no
Supervisor Fang suqiong
